Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients

Multiple Sclerosis and Related Disorders

Volumn 4, Issue 4, 2015, Pages 334-338

  Basnyat, Pabitra ^a   Hagman, Sanna ^a   Kolasa, Marcin ^a   Koivisto, Keijo ^b   Verkkoniemi Ahola, Auli ^c   Airas, Laura ^d   Elovaara, Irina ^a,e  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b SEINÄJOKI CENTRAL HOSPITAL   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

^e TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Anti JCV antibody index; Biomarkers; Multiple sclerosis; Natalizumab; Progressive multifocal leukoencephalopathy; sL selectin

Indexed keywords

BETA INTERFERON; JOHN CUNNINGHAM VIRUS ANTIBODY; L SELECTIN; NATALIZUMAB; UNCLASSIFIED DRUG; VIRUS ANTIBODY; BIOLOGICAL MARKER; IMMUNOLOGIC FACTOR;

ADULT; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; JC VIRUS; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RISK ASSESSMENT; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; IMMUNOMODULATION; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RISK; YOUNG ADULT;

ADULT; ANTIBODIES, VIRAL; BIOMARKERS; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; INTERFERON-BETA; JC VIRUS; L-SELECTIN; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NATALIZUMAB; RISK; YOUNG ADULT;

EID: 84937485577     PISSN: 22110348     EISSN: 22110356     Source Type: Journal    
DOI: 10.1016/j.msard.2015.06.008     Document Type: Article

References (32)

1. M.M. Goldenberg Multiple sclerosis review Pharm. Ther. 37 3 2012 175 184
2. M. Hutchinson Natalizumab: a new treatment for relapsing remitting multiple sclerosis Ther. Clin. Risk Manag. 3 2 2007 259 268
3. D.H. Miller, O.A. Khan, W.A. Sheremata, L.D. Blumhardt, G.P. Rice, M.A. Libonati, and et al. A controlled trial of natalizumab for relapsing multiple sclerosis N. Engl. J. Med. 348 1 2003 15 23
4. C.H. Polman, P.W. O'Connor, E. Havrdova, M. Hutchinson, L. Kappos, D.H. Miller, and et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N. Engl. J. Med. 354 9 2006 899 910
5. D.B. Clifford, A. De Luca, D.M. Simpson, G. Arendt, G. Giovannoni, and A. Nath Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases Lancet Neurol. 9 4 2010 438 446
6. R. Mancuso, M. Saresella, A. Hernis, I. Marventano, C. Ricci, S. Agostini, and et al. JC virus detection and JC virus-specific immunity in natalizumab-treated multiple sclerosis patients J. Transl. Med. 10 2012 248
7. J.R. Berger, and S. Houff Opportunistic infections and other risks with newer multiple sclerosis therapies Ann. Neurol. 65 4 2009 367 377
8. D. Buck, and B. Hemmer Biomarkers of treatment response in multiple sclerosis Expert Rev. Neurother. 14 2 2014 165 172
9. G. Bloomgren, S. Richman, C. Hotermans, M. Subramanyam, S. Goelz, A. Natarajan, and et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy N. Engl. J. Med. 366 20 2012 1870 1880
10. M.W. Ferenczy, L.J. Marshall, C.D. Nelson, W.J. Atwood, A. Nath, K. Khalili, and et al. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain Clin. Microbiol. Rev. 25 3 2012 471 506
11. N. Schwab, T. Schneider-Hohendorf, V. Posevitz, J. Breuer, K. Gobel, S. Windhagen, and et al. L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients Neurology 81 10 2013 865 871
12. N.A. Raffler, J. Rivera-Nieves, and K. Ley L-selectin in inflammation, infection and immunity Drug Discov.Today: Ther. Strateg. 2 3 2005 213 220
13. D.M. Smalley, and K. Ley L-selectin: mechanisms and physiological significance of ectodomain cleavage J. Cell. Mol. Med. 9 2 2005 255 266
14. C.H. Polman, S.C. Reingold, G. Edan, M. Filippi, H.P. Hartung, L. Kappos, and et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria" Ann. Neurol. 58 6 2005 840 846
15. J.F. Kurtzke Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology 33 11 1983 1444 1452
16. P. Lee, T. Plavina, A. Castro, M. Berman, D. Jaiswal, S. Rivas, and et al. A second-generation ELISA (STRATIFY JCV DxSelect) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification J. Clin. Virol. 57 2 2013 141 146
17. O. Outteryck, H. Zephir, J. Salleron, J.C. Ongagna, A. Etxeberria, N. Collongues, and et al. JC-virus seroconversion in multiple sclerosis patients receiving natalizumab Mult. Scler. 2013
18. T. Plavina, M. Subramanyam, G. Bloomgren, S. Richman, A. Pace, S. Lee, and et al. Anti-JCV antibody levels in serum or plasma further define risk of natalizumab-associated PML Ann. Neurol. 2014
19. A.K. Trampe, C. Hemmelmann, A. Stroet, A. Haghikia, K. Hellwig, H. Wiendl, and et al. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort Neurology 78 22 2012 1736 1742
20. L.A. Jackson, D.A. Drevets, Z.M. Dong, R.A. Greenfield, and J.W. Murphy Levels of L-selectin (CD62L) on human leukocytes in disseminated cryptococcosis with and without associated HIV-1 infection J. Infect. Dis. 191 8 2005 1361 1367
21. N. Schwab, T. Schneider-Hohendorf, J. Breuer, A. Posevitz-Fejfar, and H. Wiendl JCV index and l-selectin for natalizumab-associated PML risk stratification J. Neuroimmunol. 275 1-2 2014 24
22. I.S. Grewal, H.G. Foellmer, K.D. Grewal, H. Wang, W.P. Lee, D. Tumas, and et al. CD62L is required on effector cells for local interactions in the CNS to cause myelin damage in experimental allergic encephalomyelitis Immunity 14 3 2001 291 302
23. K. Huang, A. Kikuta, and S.D. Rosen Myelin localization of a central nervous system ligand for l-selectin J. Neuroimmunol. 53 2 1994 133 141
24. S. Wedepohl, F. Beceren-Braun, S. Riese, K. Buscher, S. Enders, G. Bernhard, and et al. L-selectin - a dynamic regulator of leukocyte migration Eur. J. Cell. Biol. 91 4 2012 257 264
25. Y. Wang, A.C. Zhang, Z. Ni, A. Herrera, and B. Walcheck ADAM17 activity and other mechanisms of soluble l-selectin production during death receptor-induced leukocyte apoptosis J. Immunol. 184 8 2010 4447 4454
26. A. Palecanda, B. Walcheck, D.K. Bishop, and M.A. Jutila Rapid activation-independent shedding of leukocyte L-selectin induced by cross-linking of the surface antigen Eur. J. Immunol. 22 5 1992 1279 1286
27. A. Ivetic Signals regulating L-selectin-dependent leucocyte adhesion and transmigration Int. J. Biochem. Cell Biol. 45 3 2013 550 555
28. B. Schleiffenbaum, O. Spertini, and T.F. Tedder Soluble L-selectin is present in human plasma at high levels and retains functional activity J. Cell Biol. 119 1 1992 229 238
29. I. Duran, E.M. Martinez-Caceres, J. Rio, N. Barbera, M.E. Marzo, and X. Montalban Immunological profile of patients with primary progressive multiple sclerosis. Expression of adhesion molecules Brain 122 12 1999 2297 2307
30. K. Baraczka, T. Pozsonyi, K. Nekam, M. Viranyi, M. Sesztak, M. Szongoth, and et al. Soluble L-selectin levels in serum and cerebrospinal fluid in patients with multiple sclerosis and systemic lupus erythematosus Acta Neurol. Scand. 102 2 2000 114 117
31. R. Mossner, K. Fassbender, J. Kuhnen, A. Schwartz, and M. Hennerici Circulating L-selectin in multiple sclerosis patients with active, gadolinium-enhancing brain plaques J. Neuroimmunol. 65 1 1996 61 65
32. H.P. Hartung, K. Reiners, J.J. Archelos, M. Michels, P. Seeldrayers, F. Heidenreich, and et al. Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging Ann. Neurol. 38 2 1995 186 193